Hot flushes and biochemical markers for cardiovascular disease: A randomized trial on hormone therapy

Climacteric

Volumn 13, Issue 5, 2010, Pages 457-466

  Tuomikoski, P ^a   Mikkola, T S ^a   Tikkanen, M J ^a   Ylikorkala, O ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

biochemical markers; cardiovascular disease; estradiol; hormone therapy; Hot flushes; medroxyprogesterone acetate; vasomotor symptoms

Indexed keywords

APOLIPOPROTEIN; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; ESTRADIOL; ESTRADIOL VALERATE; LIPID; LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; PLACEBO; SEX HORMONE BINDING GLOBULIN;

ADULT; ARTICLE; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EVALUATION; FEMALE; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HOT FLUSH; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; POSTMENOPAUSE; SEX HORMONE-BINDING GLOBULIN;

EID: 77956161005     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697131003624656     Document Type: Article

References (35)

1. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8(Suppl 1):3-63.
2. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
4. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613
5. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002;53:605-619
6. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477
7. Mikkola TS, Ylikorkala O. Hormone therapy and cardiovascular disease-still much to be learnt. Gynecol Endocrinol 2005;20:116-120
8. van der Schouw YT, Grobbee DE. Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy. Eur Heart J 2005;26:1358-1361
9. Pinkerton JV, Stovall DW. Is there an association between vasomotor symptoms and both low bone density and cardiovascular risk? Menopause 2009;16:219-223
10. Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, Hess R, Matthews KA. Hot flashes and subclinical cardiovascular disease: findings from the Study of Women's Health Across the Nation Heart Study. Circulation 2008;118:1234-1240
11. Huang AJ, Sawaya GF, Vittinghoff E, Lin F, Grady D. Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause 2009; 16:639-643
12. Svartberg J, von Muhlen D, Kritz-Silverstein D, Barrett-Connor E. Vasomotor symptoms and mortality: the Rancho Bernardo Study. Menopause 2009;16:888-891
13. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843
14. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-2033
15. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003;88:2470-2478
16. Chan DC, Watts GF. Apolipoproteins as markers and managers of coronary risk. QJM 2006;99:277-287
17. Sutton-Tyrrell K, Wildman RP, Matthews KA, et al. Sex hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women's Health Across the Nation (SWAN). Circulation 2005;111:1242-1249
18. Evangelista O, McLaughlin MA. Review of cardiovascular risk factors in women. Gender Med 2009;6:17-36.
19. Leal M, Diaz J, Serrano E, Abellan J, Carbonell LF. Hormone replacement therapy for oxidative stress in postmenopausal women with hot flushes. Obstet Gynecol 2000;95:804-809
20. Gast GC, Grobbee DE, Pop VJ, et al. Menopausal complaints are associated with cardiovascular risk factors. Hypertension 2008;51:1492-1498
21. Tuomikoski P, Mikkola TS, Hämä lä inen E, Tikkanen MJ, Turpeinen U, Ylikorkala O. Biochemical markers for cardiovascular disease in recently postmenopausal women with and without hot flashes. Menopause 2009;17:145-151
22. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-. Fertil Steril 2001;75:898-915.
23. Hemelaar M, van der Mooren MJ, Rad M, Kluft C, Kenemans P. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil Steril 2008;90:642-672
24. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95:726-731
25. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001;19:4280-4290
26. Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultralow-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007;10:120-131
27. Tuomikoski P, Ebert P, Groop PH, et al. Effect of hot flushes on vascular function: a randomized controlled trial. Obstet Gynecol 2009;114:777-785
28. Koh KK, Sakuma I. Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials? Arterioscler Thromb Vasc Biol 2004;24:1171-1179
29. Kuhl H, Stevenson J. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits-an attempt to interpret the Women's Health Initiative results. Gynecol Endocrinol 2006;22:303-317
30. Ropponen A, Aittomäki K, Tikkanen MJ, Ylikorkala O. Levels of serum C-reactive protein during oral and transdermal estradiol in postmenopausal women with and without a history of intrahepatic cholestasis of pregnancy. J Clin Endocrinol Metab 2005;90:142-146
31. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 2002;105:1436-1439
32. Sumino H, Ichikawa S, Kasama S, et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 2006;189:436-442
33. Vrablik M, Fait T, Kovar J, Poledne R, Ceska R. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. Metabolism 2008;57: 1088-1092
34. Anderson PW, Cox DA, Sashegyi A, Paul S, Silfen SL, Walsh BW. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women. Maturitas 2001;39: 71-77
35. Sowers MR, Randolph J Jr, Jannausch M, Lasley B, Jackson E, McConnell D. Levels of sex steroid and cardiovascular disease measures in premenopausal and hormone-treated women at midlife: implications for the 'timing hypothesis'. Arch Intern Med 2008;168: 2146-53